{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:47:28Z","timestamp":1765079248869},"reference-count":50,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The poor immunogenicity of the meningococcal serogroup B (MenB) capsule has led to the development of vaccines targeting subcapsular antigens, in particular the immunodominant and diverse outer membrane porin, PorA. These vaccines are largely strain specific; however, they offer limited protection against the diverse MenB-associated diseases observed in many industrialized nations. To broaden the scope of its protection, the multicomponent vaccine (4CMenB) incorporates a PorA-containing outer membrane vesicle (OMV) alongside relatively conserved recombinant protein components, including factor H-binding protein (fHbp),\n            <jats:named-content content-type=\"genus-species\">Neisseria<\/jats:named-content>\n            adhesin A (NadA), and neisserial heparin-binding antigen (NHBA). The expression of PorA is unique to meningococci (\n            <jats:named-content content-type=\"genus-species\">Neisseria meningitidis<\/jats:named-content>\n            ); however, many subcapsular antigens are shared with nonpathogenic members of the genus\n            <jats:named-content content-type=\"genus-species\">Neisseria<\/jats:named-content>\n            that also inhabit the nasopharynx. These organisms may elicit cross-protective immunity against meningococci and\/or occupy a niche that might otherwise accommodate pathogens. The potential for 4CMenB responses to impact such species (and vice versa) was investigated by determining the genetic distribution of the primary 4CMenB antigens among diverse members of the common childhood commensal,\n            <jats:named-content content-type=\"genus-species\">Neisseria lactamica<\/jats:named-content>\n            . All the isolates possessed\n            <jats:italic>nhba<\/jats:italic>\n            but were devoid of\n            <jats:italic>fhbp<\/jats:italic>\n            and\n            <jats:italic>nadA<\/jats:italic>\n            . The\n            <jats:italic>nhba<\/jats:italic>\n            alleles were mainly distinct from but closely related to those observed among a representative panel of invasive MenB isolates from the same broad geographic region. We made similar findings for the immunogenic typing antigen, FetA, which constitutes a major part of the 4CMenB OMV. Thus, 4CMenB vaccine responses may impact or be impacted by nasopharyngeal carriage of commensal neisseriae. This highlights an area for further research and surveillance should the vaccine be routinely implemented.\n          <\/jats:p>","DOI":"10.1128\/cvi.00090-13","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T04:37:44Z","timestamp":1372307864000},"page":"1360-1369","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Genetic Distribution of Noncapsular Meningococcal Group B Vaccine Antigens in Neisseria lactamica"],"prefix":"10.1128","volume":"20","author":[{"given":"Jay","family":"Lucidarme","sequence":"first","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Gilchrist","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne S.","family":"Newbold","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward B.","family":"Kaczmarski","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Zoology, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia S.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Department of Zoology, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin C. J.","family":"Maiden","sequence":"additional","affiliation":[{"name":"Department of Zoology, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","first-page":"243","volume-title":"Medical microbiology","author":"Fallon RJ","year":"2000","unstructured":"FallonRJSlackRCB. 2000. Neisseria and Moraxella (branhamella), p 243\u2013251. In GreenwoodD, Slack, RCB, Peutherer, JF (ed), Medical microbiology, 15th ed. Churchill Livingstone, London, United Kingdom.","edition":"15"},{"key":"e_1_3_3_3_2","first-page":"1307","article-title":"Human immunity to the meningococcus. I","volume":"129","author":"Goldschneider I","year":"1969","unstructured":"GoldschneiderIGotschlichECArtensteinMS. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307\u20131326.","journal-title":"The role of humoral antibodies. J. Exp. Med."},{"key":"e_1_3_3_4_2","first-page":"1327","article-title":"Human immunity to the meningococcus. II","volume":"129","author":"Goldschneider I","year":"1969","unstructured":"GoldschneiderIGotschlichECArtensteinMS. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1327\u20131348.","journal-title":"Development of natural immunity. J. Exp. Med."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800066449"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(91)90338-Y"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00118-09"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.063"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle FA","year":"1972","unstructured":"WyleFAArtensteinMSBrandtBLTramontECKasperDLAltieriPLBermanSLLowenthalJP. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514\u2013521.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang HQ","year":"2010","unstructured":"JiangHQHoisethSKHarrisSLMcNeilLKZhuDTanCScottAAAlexanderKMasonKMillerLDaSilvaIMackMZhaoXJPrideMWAndrewLMurphyEHagenMFrenchRAroraAJonesTRJansenKUZlotnickGWAndersonAS. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086\u20136093.","journal-title":"Vaccine"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1016\/j.vaccine.2011.07.124","article-title":"An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups","volume":"29","author":"Pinto VB","year":"2011","unstructured":"PintoVBMoranEECruzFWangXMFridmanAZollingerWDPrzysieckiCTBurdenR. 2011. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 29:7752\u20137758.","journal-title":"Vaccine"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.vaccine.2012.12.031","article-title":"Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"31","author":"Kaaijk P","year":"2013","unstructured":"KaaijkPvan StraatenIvan de WaterbeemdBBootEPLevelsLMvan DijkenHHvan den DobbelsteenGP. 2013. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 31:1065\u20131071.","journal-title":"Vaccine"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.033"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021911"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.05.014"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020407"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.7.4217-4223.2004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00027-10"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.02.098"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.071"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/hv.1.2.1651","article-title":"Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry","volume":"1","author":"Vipond C","year":"2005","unstructured":"VipondCWheelerJXJonesCFeaversIMSukerJ. 2005. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Hum. Vaccin. 1:80\u201384.","journal-title":"Hum. Vaccin."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2006.00057.x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.10.5955-5962.2004"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1600-0463.2012.02903.x","article-title":"Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae","volume":"120","author":"Hadad R","year":"2012","unstructured":"HadadRJacobssonSPizzaMRappuoliRFredlundHOlc\u00e9nPUnemoM. 2012. Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae. APMIS 120:750\u2013760.","journal-title":"APMIS"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.57.7.2066-2071.1989"},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1084\/jem.164.5.1735","article-title":"Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum","volume":"164","author":"Rice PA","year":"1986","unstructured":"RicePAVayoHETamMRBlakeMS. 1986. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J. Exp. Med. 164:1735\u20131748.","journal-title":"J. Exp. Med."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.5.2406-2413.1999"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5459.1816"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-11-652"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.056077-0"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/424464","article-title":"Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease","volume":"190","author":"Litt DJ","year":"2004","unstructured":"LittDJSavinoSBeddekAComanducciMSandifordCStevensJLevinMIsonCPizzaMRappuoliRKrollJS. 2004. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J. Infect. Dis. 190:1488\u20131497.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46288-0"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.186.5.1518-1530.2004"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/mic.0.26131-0","article-title":"Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component","volume":"149","author":"Thompson EA","year":"2003","unstructured":"ThompsonEAFeaversIMMaidenMC. 2003. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149:1849\u20131858.","journal-title":"Microbiology"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.4.2424-2432.2005"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00936-09"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00055-11"},{"key":"e_1_3_3_41_2","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"Hall TA","year":"1999","unstructured":"HallTA. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT. Nucleic Acids Symp. Ser. 41:95\u201398.","journal-title":"Nucleic Acids Symp. Ser."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msj030"},{"key":"e_1_3_3_44_2","first-page":"1635","article-title":"Long-term evolution of antigen repertoires among carried meningococci","volume":"277","author":"Buckee CO","year":"2010","unstructured":"BuckeeCOGuptaSKrizPMaidenMCJolleyKA. 2010. Long-term evolution of antigen repertoires among carried meningococci. Proc. Biol. Sci. 277:1635\u20131641.","journal-title":"Proc. Biol. Sci."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2008.06.010"},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nm0496-437","article-title":"The maintenance of strain structure in populations of recombining infectious agents","volume":"2","author":"Gupta S","year":"1996","unstructured":"GuptaSMaidenMCFeaversIMNeeSMayRMAndersonRM. 1996. The maintenance of strain structure in populations of recombining infectious agents. Nat. Med. 2:437\u2013442.","journal-title":"Nat. Med."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00696-07"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02422-06"},{"key":"e_1_3_3_49_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3201\/eid1603.091102","article-title":"Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany","volume":"16","author":"Elias J","year":"2010","unstructured":"EliasJSchoulsLMvan de PolIKeijzersWCMartinDRGlennieAOsterPFroschMVogelUvan der EndeA. 2010. Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany. Emerg. Infect. Dis. 16:465\u2013472.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00039-07"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013758107"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18\u201336 months: a phase 1 randomized-controlled clinical trial","volume":"31","author":"Marshall HS","year":"2012","unstructured":"MarshallHSRichmondPCNissenMDJiangQAndersonASJansenKUReynoldsGZieglerJBHarrisSLJonesTRPerezJL. 2012. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18\u201336 months: a phase 1 randomized-controlled clinical trial. Pediatr. Infect. Dis. J. 31:1061\u20131068.","journal-title":"Pediatr. Infect. Dis. J."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00090-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00090-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:49:30Z","timestamp":1627591770000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00090-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1128\/CVI.00090-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00090-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"2013-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}